Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
LEXINGTON, Mass., March 08, 2016 -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that Mani Mohindru, Ph.D., Senior Vice President, Corporate Strategy & Investor Relations, will present at the 28th Annual Roth Conference on March 15, 2016, at 10:30 a.m. Pacific Time in Dana Point, CA.
A corresponding webcast of the presentation can be accessed by visiting:
http://wsw.com/webcast/roth30/cris
The webcast will be archived shortly after the live event and available for 30 days following the conference, and also available for 30 days on the Investor Relations section of the Curis website at www.curis.com.
About Curis, Inc.
Curis is a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907, a dual HDAC and PI3K inhibitor that is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD-1 pathway/ VISTA, including PD-L1/VISTA antagonist CA-170, as well as to molecules designed to inhibit IRAK4, including CA-4948. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in other diseases including idiopathic pulmonary fibrosis and myelofibrosis.
For more information, visit Curis' website at www.curis.com.
For More Information: Mani Mohindru, Ph.D. Senior Vice President, Corporate Strategy and Investor Relations Curis, Inc. 617-503-6605 [email protected] Media Contact David Schull Russo Partners (212) 845-4271 [email protected]
